High incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patients

Bone Marrow Transplant. 2019 Dec;54(12):1923-1925. doi: 10.1038/s41409-019-0508-2. Epub 2019 Mar 19.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents, Alkylating / adverse effects*
  • Antineoplastic Agents, Alkylating / pharmacology
  • Antineoplastic Agents, Alkylating / therapeutic use
  • Bendamustine Hydrochloride / adverse effects*
  • Bendamustine Hydrochloride / pharmacology
  • Bendamustine Hydrochloride / therapeutic use
  • Female
  • Humans
  • Incidence
  • Kidney / drug effects*
  • Lymphoma / drug therapy*
  • Male
  • Multiple Myeloma / drug therapy*

Substances

  • Antineoplastic Agents, Alkylating
  • Bendamustine Hydrochloride